Tevogen Bio Holdings Inc.

AI-generated fair value estimate for this company.

Method: Net tangible asset (liquidation) value from the 6/30/2026 10-Q: total assets of $4.73M less total liabilities of $13.62M equal a stockholders' deficit of -$8.89M; since residual tangible equity is negative, value is floored at the company's unencumbered cash of $1.08M divided by 4,255,107 common shares outstanding.

Reasoning: Tevogen is a pre-revenue clinical-stage biotech with a stockholders' deficit, loan covenants in default, and no disclosed peak-sales or probability-of-success data to build a reliable risk-adjusted NPV, so a cash-based net-tangible-asset floor is the only grounded, non-speculative calculation available; the gap to the $6.60 market price reflects speculative option value on clinical and financing outcomes that cannot be rigorously quantified from public data.